The CHAMP-trial: The CHemopreventive effect of lithium on adenoma development in Familial AdenoMatous Polyposis; a single-arm, phase 2 trial

Introduction: Without prophylactic colectomy, the lifetime colorectal cancer risk in familial adenomatous polyposis (FAP) patients approaches 100%. Even after surgery, adenomas frequently develop in the residual intestinal mucosa, underscoring the need for effective chemopreventive agents. Here, we evaluated the chemopreventive effect of lithium on adenoma initiation. Methods: This single-arm, phase II trial enrolled FAP patients aged 18-35 years without history of colectomy. In an 18-month protocol, participants received daily lithium carbonate for 6-12 months. Colonoscopies with biopsies of normal mucosa were conducted at baseline, 6, 12 and 18 months. The primary endpoint was the number of APC -deficient pre-malignant clones over time, assessed by tracing mutant clones via marker gene expression. Secondary endpoints included adenoma burden, safety and tolerability. Investigators were blinded during analyses. Results: In total, 12 FAP patients underwent baseline colonoscopy, the full analysis set included 11 patients who received at least one study dose. Across all participants, no significant change in clone frequency was observed (χ 2 = 5.09, df = 3, p =0.165). Moreover, no significant effect on adenoma burden was detected. Lithium was well tolerated, with only grade 1-2 adverse events, mostly gastrointestinal (nausea and diarrhoea: n=3, 27.27%). Conclusion: This is the first trial to trace and inhibit mutant clone expansion as efficacy endpoint by boosting normal tissue fitness, aimed at preventing adenoma formation. Although lithium had no effect on the expansion APC -deficient pre-malignant clones or adenoma burden after six months, aberrant clones were detected in histologically normal mucosa, demonstrating the feasibility of tracing early tumorigenesis in humans. Trial registration: ClinicalTrials.gov (NCT05402891).

Authors

Institutions

Publication Details

Journal
Clinical and Translational Gastroenterology
Published
2026-11-19
DOI
https://doi.org/10.14309/ctg.0000000000001126
Primary Topic
Genetic factors in colorectal cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The CHAMP-trial: The CHemopreventive effect of lithium on adenoma development in Familial AdenoMatous Polyposis; a single-arm, phase 2 trial

Jasmijn D. G. Linssen, Arthur S. Aelvoet, Dewkoemar Ramsoekh, Richard Butler et al.
Clinical and Translational Gastroenterology
Genetic factors in colorectal cancer
article

The CHAMP-trial: The CHemopreventive effect of lithium on adenoma development in Familial AdenoMatous Polyposis; a single-arm, phase 2 trial

Jasmijn D. G. Linssen, Arthur S. Aelvoet, Dewkoemar Ramsoekh, Richard Butler, Mariëtte C.A. van Kouwen, Nina E. de Groot, Evelien Dekker, Sanne M. van Neerven, Louis Vermeulen, Milou S. van Driel, Lisanne E. Nijman, Clara C. Elbers, Barbara A.J. Bastiaansen
article en

Abstract

Introduction: Without prophylactic colectomy, the lifetime colorectal cancer risk in familial adenomatous polyposis (FAP) patients approaches 100%. Even after surgery, adenomas frequently develop in the residual intestinal mucosa, underscoring the need for effective chemopreventive agents. Here, we evaluated the chemopreventive effect of lithium on adenoma initiation. Methods: This single-arm, phase II trial enrolled FAP patients aged 18-35 years without history of colectomy. In an 18-month protocol, participants received daily lithium carbonate for 6-12 months. Colonoscopies with biopsies of normal mucosa were conducted at baseline, 6, 12 and 18 months. The primary endpoint was the number of APC -deficient pre-malignant clones over time, assessed by tracing mutant clones via marker gene expression. Secondary endpoints included adenoma burden, safety and tolerability. Investigators were blinded during analyses. Results: In total, 12 FAP patients underwent baseline colonoscopy, the full analysis set included 11 patients who received at least one study dose. Across all participants, no significant change in clone frequency was observed (χ 2 = 5.09, df = 3, p =0.165). Moreover, no significant effect on adenoma burden was detected. Lithium was well tolerated, with only grade 1-2 adverse events, mostly gastrointestinal (nausea and diarrhoea: n=3, 27.27%). Conclusion: This is the first trial to trace and inhibit mutant clone expansion as efficacy endpoint by boosting normal tissue fitness, aimed at preventing adenoma formation. Although lithium had no effect on the expansion APC -deficient pre-malignant clones or adenoma burden after six months, aberrant clones were detected in histologically normal mucosa, demonstrating the feasibility of tracing early tumorigenesis in humans. Trial registration: ClinicalTrials.gov (NCT05402891).

Clinical and Translational Gastroenterology
University of Cambridge (GB), The Gurdon Institute (GB), Amsterdam UMC Location University of Amsterdam (NL), Radboud University Medical Center (NL), Oncode Institute (NL), Princess Máxima Center (NL), Amsterdam University Medical Centers (NL), Cancer Center Amsterdam (NL), Amsterdam Gastroenterology Endocrinology Metabolism (NL)
Genetic factors in colorectal cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon